Bohui Innovation(SZ:300318)2024-09-03 11:25Group 1: Investor Relations Activities - The investor relations activity took place on September 3, 2024, from 16:00 to 17:00 in the company meeting room [2] - Participants included the board of directors, deputy general manager, and board secretary [2] - The meeting involved discussions on product supply and demand, specifically for albumin and immunoglobulin [2][3] Group 2: Production and Supply Chain - The company currently operates 18 plasma collection stations, with 11 owned by Hebei Bohui and 7 by Guangdong Weilen [2][3] - The plasma collection volume for the first half of 2024 was approximately 211.28 tons [3] - The design capacity of the Yunnan blood product factory is 1,500 tons of raw plasma per year, with production qualification transfer currently in process [3] Group 3: Future Plans and Capacity Expansion - The company plans to expand its plasma collection stations in suitable regions based on provincial policy planning [3] - The Hebei Bohui and Guangdong Weilen facilities are nearing their production capacity limits, with Hebei Bohui processing approximately 200 tons and Guangdong Weilen about 180 tons of plasma annually [3][4] - Future production capacity increases will be implemented gradually as new facilities come online [3] Group 4: Research and Development - Ongoing research includes stability studies for human fibrinogen and preparations for production registration of human coagulation factor VIII [4] - The company is monitoring potential future centralized procurement in various provinces and cities [4] Group 5: Financial Overview - Non-recurring gains and losses for the first half of 2024 are detailed in the company's semi-annual report [4] - The goodwill of the company primarily arises from the acquisition of Hebei Bohui and Guangdong Weilen [4]